NTHU and DAICEL of Japan to Jointly Develop Revolutionary Desktop Chemical Plant
28.10.2021 12:00:00 EEST | Business Wire | Press release
National Tsing Hua University (NTHU) and the well-known Japanese chemical company DAICEL announce a five-year joint project to integrate an innovative microfluidic system developed by scholar Kitamori Takehiko into the chemical manufacturing industry today. Total investment in the project is 450 million Japanese yen (approximately NT$110 million), and its potential to reduce energy consumption while lowering the production of carbon and waste is expected to set a new standard for sustainability in the chemical industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211028005388/en/
Prof. Kitamori Takehiko has developed an innovative microfluidic system which allows the mixing and extracting operations conventionally carried out with large-scale equipment to be performed using a glass chip the size of a business card. (Photo: National Tsing Hua University)
Prof. Kitamori, a world-renowned pioneer in microfluidic and nanofluidic technology and the former vice president of the University of Tokyo, has been serving as the Yushan Honorary Chair Professor of the Institute of Nanoengineering and Microsystems, Department of Power Mechanical Engineering at NTHU since 2020. Building on his previous research conducted at the University of Tokyo, he has developed an innovative microfluidic system which allows the mixing and extracting operations conventionally carried out with large-scale equipment to be performed using a glass chip the size of a business card and capable of combining thousands of microfluidic chips simultaneously, making it possible to create a “desktop chemical plant.”
Kitamori explained that it can be quite difficult to instantaneously mix several large barrels of chemicals with different temperatures and reaction speeds, and there may even be an explosion if the materials are not handled carefully. Thus the preferred way of blending chemicals is by passing it through a microchannel, which makes it possible to precisely control the amount of raw materials used, as well as the mixing sequence and conditions, thereby optimizing the quality of the final product.
Kitamori said that the aim of the project is to reduce the size of chemical production equipment, so that what is currently produced by a factory measuring 20 x 20 meters can be miniaturized into a system only two square meters in size. What’s more, such a system would use less energy and materials, making it less expensive, and would also produce less carbon.
Years ago, when DAICEL president Ogawa Yoshimi heard about the microfluidic technology developed by Kitamori, he was deeply impressed, and is now highly pleased that DAICEL is going to integrate this innovative technology into its operations. He is also looking forward to cooperating with NTHU in introducing this epoch-making manufacturing process to the world, which he also sees as a way of promoting sustainability and the circular economy.
Dr. Fan-gang Tseng, Vice President and Director of Research and Development, NTHU, said that he is very optimistic about the future development of the microfluidic chemical plant. He pointed out that the adoption of this microfluidic process by DAICEL—one of the largest chemical companies in Japan—and by Taiwan’s many small and medium-sized chemical factories would constitute a revolutionary leap forward, and could lead to similar processes being applied by the semiconductor and biomedical industry.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211028005388/en/
Contact information
Holly Hsueh
NTHU
(886)3-5162006
hoyu@mx.nthu.edu.tw
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 16:37:00 EEST | Press release
Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent and high-quality drafts and featuring SpeechLive's built-in integrations with leading case management platforms such as Actionstep, Clio, iManage and NetDocuments, supporting existing billing, e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
